NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $2.98 -0.08 (-2.61%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.98 0.00 (-0.17%) As of 06/24/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Cadrenal Therapeutics Stock (NASDAQ:CVKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cadrenal Therapeutics alerts:Sign Up Key Stats Today's Range$2.55▼$3.1750-Day Range$2.98▼$6.6752-Week Range$2.55▼$14.64Volume140,254 shsAverage Volume71,574 shsMarket Capitalization$8.55 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Read More Cadrenal Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCVKD MarketRank™: Cadrenal Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCadrenal Therapeutics has a consensus price target of $13.00, representing about 336.2% upside from its current price of $2.98.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($5.52) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.24% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently decreased by 3.21%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentCadrenal Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cadrenal Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $331,949.00 in company stock.Percentage Held by Insiders26.09% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVKD Stock News HeadlinesCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 CongressJune 24 at 8:00 AM | globenewswire.comInsider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells $11,489.34 in StockJune 21, 2026 | americanbankingnews.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 3,613 SharesJune 19, 2026 | insidertrades.comCadrenal Pursues Rare Pediatric Designation for TecarfarinJune 18, 2026 | tipranks.comInsider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 3,666 Shares of StockJune 16, 2026 | insidertrades.comCadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,500 SharesJune 11, 2026 | insidertrades.comCadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,898 SharesJune 6, 2026 | insidertrades.comSee More Headlines CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $6.78 at the beginning of 2026. Since then, CVKD stock has decreased by 56.0% and is now trading at $2.98. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) released its quarterly earnings data on Thursday, May, 7th. The company reported ($1.04) EPS for the quarter, beating analysts' consensus estimates of ($1.51) by $0.47. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cadrenal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Clean Energy Fuels (CLNE), Paycom Software (PAYC), uniQure (QURE), AbCellera Biologics (ABCL), Mitsubishi UFJ Financial Group (MUFG) and Oatly Group (OTLY). Company Calendar Last Earnings5/07/2026Today6/24/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CVKD's financial health is in the Red zone, according to TradeSmith. CVKD has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVKD CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year Founded2022Price Target and Rating Average Price Target for Cadrenal Therapeutics$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+336.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-411.03% Return on Assets-275.61% Debt Debt-to-Equity RatioN/A Current Ratio2.68 Quick Ratio2.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book2.55Miscellaneous Outstanding Shares2,870,000Free Float2,120,000Market Cap$8.55 million OptionableNot Optionable Beta1.59 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CVKD) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
